2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer DatabasePrognosis and risk of suicide after cancer diagnosis
Kinslow C, Kumar P, Olfson M, Wall M, Petridis P, Horowitz D, Wang T, Kachnic L, Cheng S, Prigerson H, Yu J, Neugut A. Prognosis and risk of suicide after cancer diagnosis. Cancer 2023, 130: 588-596. PMID: 38018695, DOI: 10.1002/cncr.35118.Peer-Reviewed Original ResearchConceptsRisk of suicideCancer diagnosisSuicide riskCancer sitesMonths of diagnosisRelative risk of suicideSuicide deathsBaseline suicide riskSuicide ratesNewly diagnosed cancerYears of follow-upImpact of prognosisExistential distressAssociated with suicide riskMortality ratioWeighted linear regression modelImpending deathLinear regression modelsUS populationRelative riskGeneral populationBaseline riskAssociated with overall prognosisEnd Results databaseOverall survival rateMGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patientsRisk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ
Kinslow C, Yu J, DeStephano D, Kachnic L, Cheng S, Neugut A, Horowitz D. Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ. JAMA Surgery 2023, 158: 769-771. PMID: 37074722, PMCID: PMC10116379, DOI: 10.1001/jamasurg.2023.0262.Peer-Reviewed Original ResearchAssociation of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy
Kinslow C, Mercurio A, Kumar P, Rae A, Siegelin M, Grinband J, Taparra K, Upadhyayula P, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Kachnic L, Yu J, Cheng S, Wang T. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. JAMA Oncology 2023, 9: 919-927. PMID: 37200021, PMCID: PMC10196932, DOI: 10.1001/jamaoncol.2023.0990.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse to alkylating chemotherapyMGMT promoter methylationMGMT promoter statusOverall survivalAnaplastic gliomasIDH-mutantAlkylating chemotherapyLow-gradePromoter methylationChemotherapy responseAssociated with progression-free survivalCohort studyPromoter statusAssociated with chemotherapy responseMultivariate Cox proportional hazards regression modelsClinical trials of patientsO6-methylguanine-DNA methyltransferaseCox proportional hazards regression modelsIDH wild-typeTrial of patientsIDH wild-type gliomasProportional hazards regression modelsO6-methylguanine-DNAProspective cohort studyCrazy Busy: The Blurring of Personal and Professional Boundaries as a Diversity, Equity, and Inclusion Issue
Ponce S, Seldon C, Yanagihara T, Horowitz D, Yu J, Kachnic L, Katz L. Crazy Busy: The Blurring of Personal and Professional Boundaries as a Diversity, Equity, and Inclusion Issue. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 276-279. PMID: 37179088, DOI: 10.1016/j.ijrobp.2023.01.010.Peer-Reviewed Original ResearchPractical Steps to Mitigate Cybersecurity Attacks on Radiation Oncology Practices
Yu J, Dicker A, Lester-Coll N, Tsai C, Zawalich M. Practical Steps to Mitigate Cybersecurity Attacks on Radiation Oncology Practices. Practical Radiation Oncology 2023, 13: 429-433. PMID: 37230461, DOI: 10.1016/j.prro.2023.05.001.Peer-Reviewed Original Research
2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibrationAssociation between social connectedness and stress or anxiety among older cancer survivors during the 2020–2021 winter surge of the COVID-19 pandemic
Poghosyan H, Margaryan Y, Jeon S, Edelman EJ, Yu JB. Association between social connectedness and stress or anxiety among older cancer survivors during the 2020–2021 winter surge of the COVID-19 pandemic. Journal Of Geriatric Oncology 2022, 14: 101390. PMID: 36274031, PMCID: PMC9554341, DOI: 10.1016/j.jgo.2022.10.005.Peer-Reviewed Original ResearchImpact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal Of Neurosurgery 2022, 138: 610-620. PMID: 35907197, DOI: 10.3171/2022.5.jns212761.Peer-Reviewed Original ResearchConceptsWeeks of biopsyOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingNational Cancer DatabaseInitiation of radiotherapyKaplan-Meier methodWorse overall survivalWilcoxon rank sum testEffects of confoundersRank sum testUnresected diseaseAdjuvant radiotherapyConcurrent chemotherapyMedian intervalMultivariable analysisRadiotherapy delayCancer DatabaseClinical dataBiopsyPatientsLate initiationAggressive natureRadiotherapyPotential associationFostering Transdisciplinary Collaborations in Cancer Health Economics Research
Yu J. Fostering Transdisciplinary Collaborations in Cancer Health Economics Research. JNCI Monographs 2022, 2022: 85-88. PMID: 35788381, DOI: 10.1093/jncimonographs/lgac001.Peer-Reviewed Original ResearchConceptsHealth economics researchCancer health economics researchEconomic researchHealth economicsHealth-care providersHealth-care decisionsComprehensive research questionsTransdisciplinary collaborationPotential facilitatorsParticipants' discussionsMultifaceted determinantsEconomic theoryEffective collaborationHealthEmpirical techniquesDomains of knowledgeEconomicsCollaborationCancerPanelResearch questionsProvidersParticipantsFacilitationQuestionsHealth Economics Research in Cancer Treatment: Current Challenges and Future Directions
Yu J, Schrag D, Yabroff K. Health Economics Research in Cancer Treatment: Current Challenges and Future Directions. JNCI Monographs 2022, 2022: 51-56. PMID: 35788370, DOI: 10.1093/jncimonographs/lgac009.Peer-Reviewed Original ResearchConceptsHealth economics researchMeasures of social determinants of healthCancer health economics researchNational Cancer Institute's Division of Cancer Control and Population SciencesSocial determinants of healthCost of cancer careDivision of Cancer Control and Population SciencesDeterminants of healthHealth-care systemStudies of cancer treatmentCancer treatmentCancer careIntegration of economic analysisInsurance typeHealth economistsPopulation scienceProspective economic studyHealthArea of focusWorkgroupStandard evaluationEconomic researchCancerCareClinical trialsA Special Series on Radiopharmaceutical Therapy
Yu J. A Special Series on Radiopharmaceutical Therapy. Practical Radiation Oncology 2022, 12: 283-284. PMID: 35717040, DOI: 10.1016/j.prro.2022.04.009.Peer-Reviewed Original ResearchHumansRadiopharmaceuticalsAn interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B, Ene C, Hasanov M, Derks S, Smits M, Dudani S, Heng D, Brastianos P, Bex A, Hanalioglu S, Weinberg J, Hirsch L, Carlo M, Aizer A, Brown P, Bilen M, Chang E, Jaboin J, Brugarolas J, Choueiri T, Atkins M, McGregor B, Halasz L, Patel T, Soltys S, McDermott D, Elder J, Baskaya M, Yu J, Timmerman R, Kim M, Mut M, Markert J, Beal K, Tannir N, Samandouras G, Lang F, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA A Cancer Journal For Clinicians 2022, 72: 454-489. PMID: 35708940, DOI: 10.3322/caac.21729.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaManagement of brain metastasesBrain metastasesCell carcinomaManifestation of renal cell carcinomaResistance to systemic treatmentMultimodal treatment strategiesGuiding treatment decisionsSystemic treatmentCurrent management strategiesPoor prognosisMetastasis tumorsImmune biologyBrain metastasis tumorsRadiation treatmentTreatment strategiesInternational group of expertsCarcinomaMetastasisTreatment decisionsConsensus statementPatientsInterdisciplinary consensusUnmet patient needsLiterature reviewImpact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma
Elsamadicy AA, Sandhu MRS, Freedman IG, Koo AB, Reeves BC, Yu J, Hengartner A, Havlik J, Hong CS, Rutherford HJV, Kim JA, Gerrard J, Gilmore EJ, Omay SB. Impact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma. World Neurosurgery 2022, 162: e251-e263. PMID: 35276399, DOI: 10.1016/j.wneu.2022.02.122.Peer-Reviewed Original ResearchConceptsAcute traumatic subdural hematomaTraumatic subdural hematomaHospital mortalityNonroutine dischargeSubdural hematomaExtended LOSIndependent predictorsAdult patientsBaseline frailtyMultivariate logistic regression analysisExtended hospital lengthImpact of frailtyRetrospective cohort studyNational Trauma DatabaseLogistic regression analysisRegression analysisMultivariate regression analysisHealth care expendituresFrail patientsHospital lengthCohort studySurgical evacuationFrailty indexTrauma databasePatientsChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”
Jairam V, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”. Lung Cancer 2021, 168: 84-85. PMID: 34933760, DOI: 10.1016/j.lungcan.2021.12.003.Peer-Reviewed Case Reports and Technical NotesEmergency department visits for radiation cystitis among patients with a prostate cancer history
Lee V, An Y, Park HS, Yu JB, Kim SP, Jairam V. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU International 2021, 130: 208-216. PMID: 34806813, DOI: 10.1111/bju.15650.Peer-Reviewed Original ResearchConceptsProstate cancer historyRadiation cystitisED visitsInvasive proceduresCancer historyProstate cancerRadiation therapyHigher median total chargesNationwide Emergency Department SampleEmergency department visitsEmergency Department SampleMedian total chargesPrior prostatectomyUrinary retentionBlood transfusionDepartment visitsMedian lengthEmergency departmentNational burdenSecondary diagnosisPrimary diagnosisHospital characteristicsPotential complicationsEffective modalityInvasive measuresPremetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma
Fisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters 2021, 526: 346-351. PMID: 34780851, PMCID: PMC8702484, DOI: 10.1016/j.canlet.2021.11.011.Peer-Reviewed Original ResearchConceptsMutational processesSingle ancestral lineageAncestral lineageProgression of cancerMetastatic lineagesPhylogenetic analysisGenetic resistanceEvolutionary processesExogenous mutational processesCancer evolutionConsolidative therapyMutational signature analysisEGFR-positive non-small cell lung cancerNon-small cell lung cancerKey eventsLineagesCell populationsTherapeutic resistanceLocal consolidative therapyClinical time courseCell lung cancerDisease etiologyTherapeutic decision makingCisplatin therapyLung cancerGeographic Access to Radiation Therapy Facilities in the United States
Maroongroge S, Wallington D, Taylor P, Zhu D, Guadagnolo B, Smith B, Yu J, Ballas L. Geographic Access to Radiation Therapy Facilities in the United States. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 600-610. PMID: 34762972, DOI: 10.1016/j.ijrobp.2021.10.144.Peer-Reviewed Original ResearchConceptsRadiation therapyRT facilitiesGeographic accessOlder median ageRadiation therapy facilitiesMeasures of geographic accessU.S. populationMedian ageRT accessZIP Code Tabulation AreasState purposesLogistic regressionTherapy facilitiesHigher incomeLinear acceleratorPercentage pointsImprove accessPopulation-level measuresUnited States